Recursion Pharmaceuticals Inc (RXRX) Q3 2026 Earnings Call Highlights: Durable FAP Data
Recursion Pharmaceuticals (RXRX) discussed Q3 2026 earnings, highlighting durable FAP data for REC-481, showing 92% of patients maintained polyp burden reduction after 12 weeks off treatment. CEO Najat emphasized AI-driven differentiation and data-driven capital allocation, with $535M in cash inflows from partnerships. REC-1245 showed early promise in endometrial cancer. The company guided to lower operating expenses in 2027 and has runway into 2029.
How this was made

The 30-second read
Why it matters
The call provided the first public durability metrics for REC‑481 and early efficacy signals for REC‑1245, offering a modest catalyst for the stock.
Market read
First‑time durability data may slightly improve sentiment for Recursion, but overall impact remains limited without later‑stage trial confirmation.
What to watch
Capital runway to 2029 reduces near‑term financing risk, but high cash burn could pressure valuation if milestones slip.
Background
Recursion's Q3 2026 earnings call covered pipeline updates, AI platform capabilities, and financial runway.
Ticker impact
Recursion disclosed durability data showing 92% of patients maintain polyp reduction after 12 weeks off treatment and discussed early-phase trial results for REC-481 and REC-1245.
likely slight upward pressure as investors weigh durability data against early-stage risk
First disclosure of durability metrics provides new, but limited, catalyst; impact depends on later Phase 3 outcomes.
Market effects
Highlights AI‑driven drug discovery progress, may boost interest in biotech AI peers.
US biotech sector may see modest lift; European markets less affected.
Limited to investors tracking early‑stage biotech pipelines.
Counterpoint
Durability data is early and based on small cohorts; investors may remain skeptical until Phase 3 confirms efficacy.
Key entities
- companyRecursion Pharmaceuticals Inc
US‑listed biotech developing AI‑driven therapies.
- personNajat V. (CEO)
Chief Executive Officer of Recursion.
- personVicki (CMO)
Chief Medical Officer of Recursion.




